These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 23598471)

  • 1. Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization.
    Amarasinghe A; Black S; Bonhoeffer J; Carvalho SM; Dodoo A; Eskola J; Larson H; Shin S; Olsson S; Balakrishnan MR; Bellah A; Lambach P; Maure C; Wood D; Zuber P; Akanmori B; Bravo P; Pombo M; Langar H; Pfeifer D; Guichard S; Diorditsa S; Hossain MS; Sato Y
    Vaccine; 2013 Apr; 31 Suppl 2():B108-14. PubMed ID: 23598471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capacity for a global vaccine safety system: the perspective of national regulatory authorities.
    Graham JE; Borda-Rodriguez A; Huzair F; Zinck E
    Vaccine; 2012 Jul; 30(33):4953-9. PubMed ID: 22658930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global support for new vaccine implementation in middle-income countries.
    Kaddar M; Schmitt S; Makinen M; Milstien J
    Vaccine; 2013 Apr; 31 Suppl 2():B81-96. PubMed ID: 23598496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CIOMS Guide To Vaccine Safety Communication - Executive summary.
    Bahri P; Rägo L;
    Vaccine; 2019 Jan; 37(3):401-408. PubMed ID: 30554796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
    Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
    Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS.
    ;
    Expert Rev Vaccines; 2009 Jun; 8(6):705-16. PubMed ID: 19485752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A global perspective on vaccine safety.
    Duclos P
    Vaccine; 2004 May; 22(15-16):2059-63. PubMed ID: 15121323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving global monitoring of vaccine safety: a quantitative analysis of adverse event reports in the WHO Adverse Reactions Database.
    Letourneau M; Wells G; Walop W; Duclos P
    Vaccine; 2008 Feb; 26(9):1185-94. PubMed ID: 18243428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020.
    Gandhi G; Lydon P; Cornejo S; Brenzel L; Wrobel S; Chang H
    Vaccine; 2013 Apr; 31 Suppl 2():B137-48. PubMed ID: 23598475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The imperative for stronger vaccine supply and logistics systems.
    Zaffran M; Vandelaer J; Kristensen D; Melgaard B; Yadav P; Antwi-Agyei KO; Lasher H
    Vaccine; 2013 Apr; 31 Suppl 2():B73-80. PubMed ID: 23598495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supporting countries in establishing and strengthening NITAGs: lessons learned from 5 years of the SIVAC initiative.
    Adjagba A; Senouci K; Biellik R; Batmunkh N; Faye PC; Durupt A; Gessner BD; da Silva A
    Vaccine; 2015 Jan; 33(5):588-95. PubMed ID: 25545597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis.
    Olsson S; Pal SN; Stergachis A; Couper M
    Drug Saf; 2010 Aug; 33(8):689-703. PubMed ID: 20635827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.
    LaRussa PS; Edwards KM; Dekker CL; Klein NP; Halsey NA; Marchant C; Baxter R; Engler RJ; Kissner J; Slade BA
    Pediatrics; 2011 May; 127 Suppl 1():S65-73. PubMed ID: 21502239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Landscape analysis of pharmacovigilance and related practices among 34 vaccine manufacturers' from emerging countries.
    Hartmann K; Pagliusi S; Precioso A
    Vaccine; 2020 Jul; 38(34):5490-5497. PubMed ID: 32591289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine safety monitoring systems in developing countries: an example of the Vietnam model.
    Ali M; Rath B; Thiem VD
    Curr Drug Saf; 2015; 10(1):60-7. PubMed ID: 25859677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing a national system for dealing with adverse events following immunization.
    Mehta U; Milstien JB; Duclos P; Folb PI
    Bull World Health Organ; 2000; 78(2):170-7. PubMed ID: 10743281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic and immunisation safety surveillance characteristics of countries implementing no-fault compensation programmes for vaccine injuries.
    Mungwira RG; Maure CG; Zuber PLF
    Vaccine; 2019 Jul; 37(31):4370-4375. PubMed ID: 31213377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization safety priority project at the World Health Organization.
    Duclos P; Delo A; Aguado T; Bilous J; Birmingham M; Kieny MP; Milstien J; Wood D; Tarantola D
    Semin Pediatr Infect Dis; 2003 Jul; 14(3):233-9. PubMed ID: 12913836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.